Physician profile
Michael Sheu
NPI 1801475264
$721.53
in general payments reported to CMS, 2019-2025
13 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.53 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $348.69 | 2025 | Jakafi, Niktimvo, Niktimvo |
| Pfizer INC. | $50.63 | 2025 | |
| Genzyme Corporation | $50.48 | 2025 | |
| Emd Serono, INC. | $47.66 | 2025 | |
| Celgene Corporation | $42.80 | 2025 | Opdivo |
| Abbvie INC. | $32.43 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $26.53 | 2025 | Calquence |
| Pharmaessentia USA Corporation | $22.70 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $21.87 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $21.28 | 2025 | Yescarta |
| Daiichi Sankyo INC. | $20.81 | 2025 | Enhertu |
| Janssen Biotech, INC. | $18.94 | 2025 | Tecvayli |
| Merck Sharp & Dohme LLC | $16.71 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sheu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.